News Headline Summary

Blue Cross have changed their position on Vermillion's (VRML) OVA1 ovarian cancer test from medically necessary to investigational for all indications

Reaction details (12:49)

- VRML shares dipped 4.95% to USD 1.35 per share in the immediate reaction.

21 Dec 2012 - 12:47 - Equities - Source: B4THESTREET.COM

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: